Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 2/2006

01-02-2006 | Review Article

NSAID-Associated Adverse Effects and Acid Control Aids to Prevent Them

A Review of Current Treatment Options

Authors: Dr Jørgen Naesdal, Kurt Brown

Published in: Drug Safety | Issue 2/2006

Login to get access

Abstract

NSAIDs are central to the clinical management of a wide range of conditions. However, NSAIDs in combination with gastric acid, which has been shown to play a central role in upper gastrointestinal (GI) events, can damage the gastroduodenal mucosa and result in dyspeptic symptoms and peptic lesions such as ulceration.
Literature
1.
Singh G, Triadafilopoulos G. Epidemiology of NSAID-induced gastrointestinal complications. J Rheumatol 1999; 26Suppl. 26: 18–24
2.
Cullen DJ, Seager JM, Holmes S, et al. Pharmacoepidemiology of non-steroidal anti-inflammatory drug use in Nottingham general practices. Aliment Pharmacol Ther 2000; 14: 177–85PubMedCrossRef
3.
4.
Bedson J, Whitehurst T, Lewis M, et al. Factors affecting over-the-counter use of aspirin in the secondary prophylaxis of cardiovascular disease. Br J Gen Pract 2001; 51: 1001–3PubMed
5.
Jones R. Nonsteroidal anti-inflammatory drug prescribing: past, present, and future. Am J Med 2001; 110(1A): 4S–7SPubMedCrossRef
6.
Czernichow P, Merle V. Epidemiology of digestive complications associated with low-dose aspirin [in French]. Gastroenterol Clin Biol 2004; 28: 37–44CrossRef
7.
Bloom BS. Cost of treating arthritis and NSAID-related gastrointestinal side-effects. Aliment Pharmacol Ther 1988; 2Suppl. 1: 131–8PubMed
8.
Smalley WE, Griffin MR, Fought RL, et al. Excess costs from gastrointestinal disease associated with NSAIDs. J Gen Intern Med 1996; 11: 461–9PubMedCrossRef
9.
Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998; 105(1B): 31S–8SPubMedCrossRef
10.
Lanas A. Gastrointestinal injury from NSAID therapy: how to reduce the risk of complications. Postgrad Med 2005; 117(6): 23–8, 31PubMedCrossRef
11.
Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971; 231: 232–5
12.
Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004; 56: 387–437PubMedCrossRef
13.
Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995; 44: 1–10PubMedCrossRef
14.
Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000; 69: 145–82PubMedCrossRef
15.
Wallace JL, McKnight W, Reuter BK, et al. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000; 119: 706–14PubMedCrossRef
16.
Takeeda M, Hayashi Y, Yamato M, et al. Roles of endogenous prostaglandins and cyclooxygenase isozymes in mucosal defense of inflamed rat stomach. J Physiol Pharmacol 2004; 55: 193–205PubMed
17.
Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 1888–99PubMedCrossRef
18.
Singh G, Rosen Ramey D. NSAID-induced gastrointestinal complications: the ARAMIS perspective: 1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl 1998; 51: 8–16PubMed
19.
Straus WL, Ofman JJ, MacLean C, et al. Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia definitions. Am J Gastroenterol 2002; 97: 1951–8PubMedCrossRef
20.
Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am 1996; 6: 489–504PubMed
21.
Brown GJ, Yeomans ND. Prevention of the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs: the role of proton pump inhibitors. Drug Saf 1999; 21: 503–12PubMedCrossRef
22.
Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987; 28: 527–32PubMedCrossRef
23.
Larkai EN, Smith JL, Lidsky MD, et al. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987; 82: 1153–8PubMed
24.
Singh G, Ramey DR, Morfeld D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: a prospective observational cohort study. Arch Intern Med 1996; 156: 1530–6PubMedCrossRef
25.
Brooks PM, Day RO. Nonsteroidal anti-inflammatory drugs: differences and similarities. N Engl J Med 1991; 324: 1716–25PubMedCrossRef
26.
Hardin JG, Longenecker GL. Handbook of drug therapy in rheumatic disease. Pharmacology and clinical aspects. Boston (MA): Little Brown Co., 1992
27.
Bjarnason I, Hayllar J, Macpherson AJ, et al. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993; 104: 1832–47PubMed
28.
Aalykke C, Hallas J, Lauritsen JM, et al. Role of NSAID use in inflammatory bowel disease: a 5-year follow-up study [abstract]. Gastroenterology 2000; 118Suppl. 2: A–869
29.
Allen A, Flemstrom G, Garner A, et al. Gastroduodenal mucosal protection. Physiol Rev 1993; 73: 823–57PubMed
30.
Wallace JL, Whittle BJR. The role of extracellular mucus as a protective cap over gastric mucosal damage. Scand J Gastroenterol 1986; 21Suppl. 125: 79–84CrossRef
31.
Wallace JL, McKnight GW. The mucoid cap over superficial gastric damage in the rat: a high pH microenvironment dissipated by nonsteroidal anti-inflammatory drugs and endothelin. Gastroenterology 1990; 99: 295–304PubMed
32.
Levine RA, Schwartzel EH. Effect of indomethacin on basal and histamine-stimulated human gastric acid secretion. Gut 1984; 25: 718–22PubMedCrossRef
33.
Savarino V, Mela GS, Zentilin P, et al. Effect of one-month treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) on gastric pH of rheumatoid arthritis patients. Dig Dis Sci 1998; 43: 459–63PubMedCrossRef
34.
Feldman M, Colturi TJ. Effect of indomethacin on gastric acid and bicarbonate secretion in humans. Gastroenterology 1984; 87: 1339–43PubMed
35.
Shiotani A, Yamaoka Y, El-Zimaity HMT, et al. NSAID gastric ulceration: predictive value of gastric pH, mucosal density of polymorphonuclear leukocytes, or levels of IL-8 or nitrite. Dig Dis Sci 2002; 47: 38–43PubMedCrossRef
36.
Elliott SL, Ferris RJ, Giraud AS, et al. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin Exp Pharmacol Physiol 1996; 23: 432–4PubMedCrossRef
37.
Cheatum DE, Arvanitakis C, Gumpel M, et al. An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs. Clin Ther 1999; 21: 992–1003PubMedCrossRef
38.
Carson JL, Willett LR. Toxicity of nonsteroidal anti-inflammatory drugs: an overview of the epidemiologic evidence. Drugs 1993; 46Suppl. 1: 243–8PubMedCrossRef
39.
Fries JF, Williams CA, Bloch DA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991; 91: 213–22PubMedCrossRef
40.
Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991; 115: 787–96PubMed
41.
Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002; 123: 1006–12PubMedCrossRef
42.
Garcia Rodriguez LA, Harnandez-Diaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol 2001; 52: 563–71PubMedCrossRef
43.
Henry D, Lim LL-Y, Garcia Rodriquez LA, et al. Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563–6PubMedCrossRef
44.
Richy F, Bruyere O, Ethgen O, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 2004; 63: 759–66PubMedCrossRef
45.
Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999; 117: 776–83PubMedCrossRef
46.
Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282: 1921–8PubMedCrossRef
47.
Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520–8PubMedCrossRef
48.
Goldstein JL, Silverstein FE, Agrawal NM, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95: 1681–90PubMedCrossRef
49.
Goldstein JL, Correa P, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001; 96: 1019–27PubMedCrossRef
50.
Hawkey C, Laine L, Simon T, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. Arthritis Rheum 2000; 43: 370–7PubMedCrossRef
51.
Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247–55PubMedCrossRef
52.
Hawkey CJ, Laine L, Simon T, et al. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. Gut 2003; 52: 820–6PubMedCrossRef
53.
Lisse JR, Perlman M, Johansson G, et al. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Intern Med 2003; 139: 539–46PubMed
54.
Watson DJ, Harper SE, Zhao PL, et al. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000; 160: 2298–3003CrossRef
55.
Goldstein JL, Eisen GM, Burke TA, et al. Dyspepsia tolerability from the patients’ perspective: a comparison of celecoxib with diclofenac. Aliment Pharmacol Ther 2002; 16: 809–27CrossRef
56.
Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 1929–33PubMedCrossRef
57.
Tacconelli S, Capone ML, Patrignani P. Clinical pharmacology of novel COX-2 inhibitors. Curr Pharm Des 2004; 10: 589–601PubMedCrossRef
58.
Hunt RH, Harper S, Watson DJ, et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003; 98: 1725–33PubMedCrossRef
59.
Goldstein JL, Eisen GM, Agrawal N, et al. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib. Aliment Pharmacol Ther 2004; 20: 527–38PubMedCrossRef
60.
Harris SI, Stoltz RR, LeComte D, et al. Parecoxib sodium demonstrates gastrointestinal safety comparable to placebo in healthy subjects. J Clin Gastroenterol 2004; 38: 575–80PubMedCrossRef
61.
Kivitz AJ, Nayiager S, Schimansky T, et al. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Aliment Pharmacol Ther 2004; 19: 1189–98PubMedCrossRef
62.
Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutics Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised, controlled trial. Lancet 2004; 364: 665–74PubMedCrossRef
63.
Watson DJ, Bolognese JA, Yu C, et al. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Curr Res Med Opin 2004; 20: 1899–908CrossRef
64.
Hawkey CC, Svoboda P, Fiederowicz-Fabrycy IF, et al. Gastroduodenal safety and tolerability of lumiracoxib compared with ibuprofen and celecoxib in patients with osteoarthritis. J Rheumatol 2004; 31: 1804–10PubMed
65.
66.
Furberg CD, Psaty BM, Fitzgerald GA. Parecoxib, valdecoxib, and cardiovascular risk. Circulation 2005; 111: 249PubMedCrossRef
67.
Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationship among dose, effectiveness, and side effects. Chest 2001; 119: 39S–63SPubMedCrossRef
68.
Fitzgerald DJ, Roy L, Catella F, et al. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983–9PubMedCrossRef
69.
Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954–9PubMedCrossRef
70.
Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092–102PubMedCrossRef
71.
Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071–80PubMedCrossRef
72.
Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081–91PubMedCrossRef
73.
U.S. Food and Drug Administration [online]. Available from URL: http://​www.​fda.​gov/​cder/​drug/​infopage/​cox2/​COX2qa.​htm [Accessed 2005 Apr 14]
74.
Alvaro-Gracia JM. Licofelone: clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis. Rheumatology 2004; 43Suppl. 1: I21–5PubMedCrossRef
75.
Bias P, Buchner A, Klesser B, et al. The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial. Am J Gastroenterol 2004; 99: 611–8PubMedCrossRef
76.
Hallas J, Lauritsen J, Villadsen HD, et al. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates. Scand J Gastroenterol 1995; 30: 438–44PubMedCrossRef
77.
Piper JM, Ray WA, Daugherty JR, et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114: 735–40PubMed
78.
Shorr RI, Ray WA, Daugherty JR, et al. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993; 153: 1665–70PubMedCrossRef
79.
Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic ulcer disease: a meta-analysis. Lancet 2002; 359: 14–22PubMedCrossRef
80.
Hudson N, Balsitis M, Filipowicz F, et al. Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993; 34: 748–51PubMedCrossRef
81.
Seager JM, Hawkey CJ. ABC of the upper gastrointestinal tract: indigestion and non-steroidal anti-inflammatory drugs. BMJ 2001; 323: 1236–9PubMedCrossRef
82.
Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241–9PubMed
83.
Elliott SL, Yeomans ND, Buchanan RRC, et al. Efficacy of 12 months’ misoprostol as prophylaxis against NSAID-induced gastric ulcers: a placebo controlled trial. Scand J Gastroenterol 1994; 23: 171–6
84.
Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995; 123: 344–50PubMed
85.
Robinson MG, Griffin JW, Bowers J, et al. Effect of ranitidine on gastroduodenal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci 1989; 34: 424–8PubMedCrossRef
86.
Ehsanullah RS, Page MC, Tildesley G, et al. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ 1988; 297: 1017–21PubMedCrossRef
87.
Battler NY, Abuksis G, Gal E, et al. Endoscopy in asymptomatic minidose aspirin consumers. Dig Dis Sci 2005; 50: 78–80PubMedCrossRef
88.
Walt RP, Gomes MD, Wood EC, et al. Effect of daily oral omeprazole on 24 hour intragastric acidity. BMJ 1983; 287: 12–4PubMedCrossRef
89.
Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996; 334: 1435–9PubMedCrossRef
90.
Lancaster-Smith MJ, Jaderberg ME, Jackson DA. Ranitidine in the treatment of non-steroidal anti-inflammatory drug associated gastric and duodenal ulcers. Gut 1991; 32: 252–5PubMedCrossRef
91.
Hudson N, Taha AS, Russell RI, et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology 1997; 112: 1817–22PubMedCrossRef
92.
Van Groenendael JHLM, Markusses HM, Dijkmans BAC, et al. The effect of ranitidine in NSAID-related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol 1996; 15: 450–6PubMedCrossRef
93.
Prichard PJ, Jones DB, Yeomans ND, et al. The effectiveness of ranitidine in reducing gastric-acid secretion decreases with continued therapy. Br J Clin Pharmacol 1986; 22: 663–8PubMedCrossRef
94.
Cullen D, Bardhan KD, Eisner M, et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 1998; 12: 135–40PubMedCrossRef
95.
Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 338: 727–34PubMedCrossRef
96.
Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 338: 719–26PubMedCrossRef
97.
Rose P, Huang B, Lukasik N, et al. Evidence that lansoprazole is effective in preventing NSAID induced ulcers [abstract]. Gastroenterology 1999; 116: A295
98.
Scheiman JM, Vakil N, Hawkey CJ, et al. Esomeprazole prevents gastric and duodenal ulcers in at-risk patients on continuous non-selective or COX-2-selective NSAID therapy [abstract no. 638]. Gastroenterology 2004; 126Suppl. 2: A–82
99.
Yeomans N, Scheiman JM, Hawkey CJ, et al. An evidence-based analysis of esomeprazole therapy versus placebo for the prevention of gastric or duodenal ulcers in at-risk continuous NSAID users [abstract no. W1278]. Gastroenterology 2004; 126Suppl. 2: A–604
100.
Agrawal NM, Campbell DR, Safdi MA, et al. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. Arch Intern Med 2000; 160: 1455–61PubMedCrossRef
101.
Hawkey CJ, Yeomans ND, Jones R, et al. Esomeprazole improves quality of life in patients with upper GI symptoms associated with long-term NSAID therapy [abstract]. Gastroenterology 2003; 124(4 Suppl. 1): A–107
102.
Yeomans ND, Hawkey CJ, Jones R, et al. Esomeprazole provides effective control of NSAID-associated upper GI symptoms in patients continuing to take NSAIDs [abstract]. Gastroenterology 2003; 124(4 Suppl. 1): A–107
103.
Hawkey CJ, Lanas AI. Doubt and certainty about nonsteroidal anti-inflammatory drugs in the year 2000: a multidisciplinary expert statement. Am J Med 2001; 110: 79S–100SPubMedCrossRef
Metadata
Title
NSAID-Associated Adverse Effects and Acid Control Aids to Prevent Them
A Review of Current Treatment Options
Authors
Dr Jørgen Naesdal
Kurt Brown
Publication date
01-02-2006
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 2/2006
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200629020-00002

Other articles of this Issue 2/2006

Drug Safety 2/2006 Go to the issue

Original Research Article

HMG CoA Reductase Inhibitors and Impotence

Original Research Article

The Effect of Detection Approaches on the Reported Incidence of Tenfold Errors

Review Article

Interactions between Antiepileptic and Antipsychotic Drugs

Original Research Article

Ophthalmological Events in Patients Receiving Risedronate

Review Article

Current Understanding of Contrast Media Reactions and Implications for Clinical Management

Original Research Article

Adverse Drug Reaction-Related Hospitalisations